Company intelligence / Profile preview

March Investors

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

MB-105 demonstrated a 44 percent patient response rate in Phase 1 trials, with multiple long-term and durable complete responses and a favorable safety profile with limited CAR-associated toxicities[6]. Phase 2 trial began dosing patients in early 2025, aiming to enroll approximately 46 patients[5].

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Biotech

Partnerships

Volnay TherapeuticsCTMC (joint effort between National Resilience and MD Anderson Cancer Center)

Beyond the preview

Go deeper on March Investors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on March Investors.

Explore the full profile